Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F11 | P03951 | 2/20 | 0.43 |
| ▸ | CYP17A1 | P05093 | 3/20 | 0.37 |
| ▸ | PTPRB | P23467 | 10/20 | 0.36 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.36 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.35 |
| ▸ | EGFR | P00533 | 1/20 | 0.34 |
| ▸ | SRC | P12931 | 1/20 | 0.34 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL478745 | 0.87 | F11 (0.46) | F11CYP17A1PTPRBPSMB8MAP4K4 | |
| SCHEMBL478746 | 0.87 | F11 (0.46) | F11CYP17A1PTPRBPSMB8MAP4K4 | |
| SCHEMBL479068 | 0.87 | F11 (0.44) | F11CYP17A1PTPRBPSMB8MAP4K4 | |
| SCHEMBL478811 | 0.85 | F11 (0.58) | F11PTPRB | |
| SCHEMBL478617 | 0.83 | F11 (0.49) | F11CYP17A1PTPRB | |
| SCHEMBL478802 | 0.82 | F11 (0.44) | F11CYP17A1PTPRBPSMB8 | |
| SCHEMBL478976 | 0.81 | F11 (0.49) | F11 | |
| SCHEMBL479282 | 0.80 | F11 (0.37) | F11CYP17A1PTPRBPSMB8MAP4K4 | |
| SCHEMBL478793 | 0.79 | SYK (0.48) | F11PTPRB | |
| SCHEMBL478814 | 0.78 | F11 (0.43) | F11CYP17A1PTPRBBRD4CREBBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8324199-B2 | Pyridazine derivatives as factor xia inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-12-04 | — | — | US | disclosed |
| EP-2265601-B1 | PYRIDAZINE DERIVATIVES AS FACTOR XIA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2012-02-01 | — | — | EP | disclosed |
| US-20110021492-A1 | PYRIDAZINE DERIVATIVES AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2011-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021492-A1 | PYRIDAZINE DERIVATIVES AS FACTOR XIA INHIBITORS | F11, F12, TFPI2 | F11 1/4885CYP17A1 1025/4885PTPRB 2306/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.